Welcome to our dedicated page for International Stem Cell SEC filings (Ticker: ISCO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The International Stem Cell Corporation (ISCO) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports and other documents filed with the U.S. Securities and Exchange Commission. These filings complement ISCO’s public news releases by detailing corporate actions, governance decisions, financing arrangements and aspects of its capital structure.
For ISCO, key SEC filings include Form 8-K current reports that describe material events. Examples disclosed in recent filings include the results of an annual meeting of stockholders, where directors were elected and advisory votes on executive compensation and the frequency of such votes were held, and an agreement to extend the maturity date of a loan from a related party, including the principal amount, interest rate and revised due date. These documents also show that ISCO has no securities registered on a national securities exchange under Section 12(b) of the Exchange Act.
Through this page, users can review how International Stem Cell Corporation reports items such as redeemable convertible preferred stock, non-redeemable convertible preferred stock, common stock and related party notes payable across its filings. Stock Titan enhances access to these materials with AI-powered summaries that explain the main points of lengthy documents, helping readers understand the implications of corporate actions, financing terms and stockholder votes without reading every line.
Filings are updated as they become available from EDGAR, allowing investors and researchers to monitor new 8-Ks and other reports related to ISCO’s governance, financing and structural changes alongside the company’s clinical and commercial activities.
International Stem Cell Corporation is a clinical-stage biotechnology company developing therapies based on human parthenogenetic stem cells, alongside two small revenue-generating units in anti-aging skin care and research cell products. It generated $9.1 million of revenue in both 2025 and 2024 from these commercial businesses, but none yet from its core therapeutic programs.
The company’s lead program uses hpSC-derived neural stem cells (ISC-hpNSC®) for Parkinson’s disease, where a Phase 1 dose-escalation trial has been completed with encouraging safety and preliminary efficacy signals. Additional preclinical work targets traumatic brain injury and stroke. ISCO holds 36 patents and operates cGMP manufacturing in Maryland plus R&D in California.
Management highlights substantial risks: the business remains at an early stage, has a long history of operating losses, and its auditors have expressed substantial doubt about its ability to continue as a going concern. ISCO states it will need significant additional capital to fund ongoing operations and further clinical development, and faces intense competition, complex global regulation, and evolving ethical and legal frameworks around stem cell technologies.
International Stem Cell Corporation reported the results of its annual stockholder meeting held on June 17, 2025. Stockholders elected four directors to serve until the 2026 annual meeting, including Andrey Semechkin and Russell Kern, each receiving 2,457,143 votes for with no votes withheld, and Donald A. Wright and Paul V. Maier, each receiving 7,772,429 votes for and 19,267 votes withheld. Stockholders also approved, on an advisory basis, the compensation of the company’s named executive officers, with 7,715,844 votes for, 73,393 against, and 2,459 abstentions. In addition, stockholders advised that future votes on executive compensation should be held every three years, with 7,593,833 votes favoring a three-year frequency, compared with 142,581 for one year and 50,443 for two years.
International Stem Cell Corporation reported Q3 2025 results. Product sales were $2.369 million, up from $2.179 million a year ago, and income from operations was $94 thousand versus a prior loss. Net income was $57 thousand compared with a net loss of $125 thousand in Q3 2024.
Cash was $966 thousand at quarter-end, and management disclosed “substantial doubt” about the company’s ability to continue as a going concern without additional financing or extensions of existing financing. A related party note payable is presented at $3.305 million within current liabilities, and its maturity was extended to September 15, 2026.
Sales were led by the biomedical segment (LCT) with $2.204 million; the skin care segment (LSC) contributed $165 thousand. One customer accounted for 54% of consolidated product sales in the quarter and 62% of accounts receivable as of September 30, 2025. Basic and diluted EPS were $0.00, with 8,004,389 weighted-average shares.
International Stem Cell Corporation reported that it has amended a loan agreement with its Co-Chairman and Chief Executive Officer, Dr. Andrey Semechkin. The company and Dr. Semechkin agreed to extend the maturity date of a $2,500,000 loan, originally documented in a promissory note dated September 15, 2024, so that the loan is now due on September 15, 2026 instead of the prior 2025 maturity.
The outstanding principal under the note continues to accrue interest at an annual rate of 5.5%, and the company may prepay the note at any time without penalty. The amended note was issued on September 15, 2025, and a form of the note is included as Exhibit 10.1, providing the detailed terms of this insider financing arrangement.